Unknown

Dataset Information

0

Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.


ABSTRACT: BACKGROUND:Patients with both diabetes mellitus (DM) and chronic kidney disease (CKD) are a subpopulation characterized by ultrahigh ischemic and bleeding risk after percutaneous coronary intervention. There are limited data on the impact of ticagrelor monotherapy among these patients. METHODS:In this post hoc analysis of the GLOBAL-LEADERS trial, the treatment effects of the experimental (one-month dual-antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus the reference regimen (12-month DAPT followed by 12-month aspirin alone) were analyzed according to DM/CKD status. The primary endpoint was a composite endpoint of all-cause death or new Q-wave myocardial infarction at 2-years. The patient-oriented composite endpoint (POCE) was defined as the composite of all-cause death, any stroke, site-reported MI and any revascularization, whereas net adverse clinical events (NACE) combined POCE with BARC type 3 or 5 bleeding events. RESULTS:At 2 years, the DM?+?/CKD?+?patients had significantly higher incidences of the primary endpoint (9.5% versus 3.1%, adjusted HR 2.16; 95% CI [1.66-2.80], p?

SUBMITTER: Gao C 

PROVIDER: S-EPMC7568378 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Patients with both diabetes mellitus (DM) and chronic kidney disease (CKD) are a subpopulation characterized by ultrahigh ischemic and bleeding risk after percutaneous coronary intervention. There are limited data on the impact of ticagrelor monotherapy among these patients.<h4>Methods</h4>In this post hoc analysis of the GLOBAL-LEADERS trial, the treatment effects of the experimental (one-month dual-antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) vers  ...[more]

Similar Datasets

| S-EPMC7270912 | biostudies-literature
| S-EPMC6764000 | biostudies-literature
| S-EPMC8649516 | biostudies-literature
2023-10-24 | PXD042188 | Pride
| S-EPMC9238541 | biostudies-literature
| S-EPMC8483765 | biostudies-literature
| S-EPMC9300025 | biostudies-literature
| S-EPMC7845141 | biostudies-literature
| S-EPMC10445191 | biostudies-literature
| S-EPMC6402882 | biostudies-literature